CARICOL takes papaya one step further
The patented formula increases the digestive properties of the papaya by seven times, creating CARICOL, a natural “power concentrate” for the effective regulation and support of the digestion.
The production of CARICOL is based on an energizing process, just like the preparation processes known from the traditional Chinese and ayurvedic dietetics.
CARICOL is an energized food and therefore activates those energy circles in the body, that are significantly involved in the digestion process.
The effectiveness of this special preparation process is also scientifically measured.
Analyses showed that the enzyme activity in CARICOL is four times higher than in the ripe fruit prior to the production process.
The effects of CARICOL on the digestion were tested and proved in various medical studies:
|
 |
Study – Irritable bowel syndrome (IBS)
Ordination Dr.Vogelsang (specialist for functional and inflammatory gastro-intestinal diseases)
Directed by Univ.Prof. Dipl.Ing. Dr. H.Vogelsang, department for gastro enterology at the University hospital in Vienna
Background: One fifth of the population in industrial countries suffers from irritable bowel syndrome (IBS), that can not really lead to serious complications, but massively affects the patients´ well being and their ability to work. To this day, there is still no causal therapy. Because it is not a life threatening illness, “harmless and free of adverse reactions” are prime principles for any kind of treatment.
CARICOL was proven effective for constipation and diarrhoea. Yet irritable bowel syndrome often comes along with both diarrhoea and constipation, we made a prospective study aiming at the potential of
CARICOL in this respect.
Methods: 15 patients with diarrhoea dominated IBS were administered 2 CARICOL sticks per day over 2 months. The dosage was reduced or increased depending on the frequency of bowel movements.
Data was gathered via a questionnaire, in which both IBS symptoms as well as psychological parameters such as anxiety and depression were factored.
Conclusion: 87% of the participants showed reductions in pain ranging from slight to complete due to the treatment. Mood and anxiety could also be improved, though the therapy showed no influence on depressions. Thus, CARICOL can be included among the standardized therapeutics for irritable bowel syndrome. CARICOL is a symptomatic therapy aid, which could well be compared with other standard therapeutics related to the irritable bowel syndrome. A positive effect on diarrhoea dominated irritable bowel syndrome can be achieved within 4 weeks, when taking 2 sticks per day.
Average Improvements
Geriatric Center Baumgarten, Vienna
Directed by Dr. Peter M. Bernecker MD, head of department for internal medicine, and Dr. Theresia Maier-Dobersberger MD, specialist for internal medicine and gastro-enterology
In this study, 40 patients diagnosed with ”chronic constipation” were administered CARICOL. Their bowel movement was documented over a time span of 11 weeks altogether.
During a pre-test phase of 3 weeks, in which use of all laxatives was terminated, an average ”degree of constipation” (number of days without bowel movement divided by number of days with) of 0.6 was computed. Subsequently, the patients were given 2 doses of 2 tbsp CARICOLdaily for five weeks, resulting in a significant decrease to 0.4. in other words, days with bowel movements increased by 50% with respect to each day without a movement. During a second therapy phase, 18 patients took CARICOL for three more weeks, this time dosage was cut in half (2 tbsp daily) with a further significant reduction in the degree of constipation to 0.3 as a result.
During the beginning of the therapy phase, 9 patients had to be administered ”escape medication” (2 Microclist after 3 days without bowel movement), this intervention was necessary for only 3 patients at the end. After the second phase (half dose) only 1 patient required such intervention.
Committee for Assisted Living ResidencesVienna
Directed by Dr. Herta Bayer MD,medical supervisor and Dr. Heide Seppele, general practitioner
10 patients diagnosed with ”chronic diarrhoea” were administered CARICOL and their bowel movements documented over a 7-week time frame. At the beginning of the three-week long pre-study phase, the patients had mushy or liquid stool on average 4 days a week, and normal stool on 2.5 days.
Shortly after starting therapy, the patients had normal stool half the time, and during the last week of the study, normal bowel movements were observed for 5 days a week on average.
All test subjects experienced normal stool more often than mushy/liquid stool, hence a significant improvement of patients’ bowel activity had been confirmed.
Comparison of the effectiveness of CARICOL with a customary
papaya fruit puree
Geriatric Center Wienerwald, Vienna
In this study, 6 patients diagnosed with “chronic constipation” were administered CARICOL (called group “C”), 10 patients diagnosed with “chronic constipation” were administered regular Papaya puree (called group “P”). Their bowel movements were documented over a time span of 6 weeks altogether. During a pre-test phase of 3 weeks, use of all laxatives was terminated.
For evaluating the effect on the digestion, the number of required escape medication (2 Lecicarbon after 3 days without bowel movement) was compared.
In group "C“ an escape medication had to be administered 18 times during the pre-test phase - During the therapy phase with CARICOL, an escape medication was necessary 6 times only. In other words the administration of an escape medication could be reduced at 66%.
In group „P“ an escape medication had to be administered 29 times during the pre-test phase, during the therapy phase with a regular Papaya puree an escape medication was necessary still 26 times. In other words, the administration of an escape medication could be reduced by 9% only.
